Docetaxel and Vinorelbine Plus Filgrastim with Weekly Trastuzumab for HER-2 Positive, Stage IV Breast Cancer, Phase II Pilot

Women with Stage IV, HER-2 positive breast cancer; HER-2 status confirmed by FISH in the adjuvant or metastatic setting; no more than one prior adjuvant or neoadjuvant regimen; no prior docetaxel therapy (paclitaxel is allowed); no prior vinorelbine; prior hormonal therapy OK but must be stopped prior to registration; all prior chemotherapy must be completed at least six months before registration; prior RT OK but must have been completed at least 3 weeks prior to registration; no brain or CNS disease or evidence of brain or CNS metastases; no pre-existing >= Grade 2 motor or sensory peripheral neruopathy except for abnormalities due to cancer; no know sensitivity to E. coli derived proteins; no history of severe hypersensitivity to drugs formulated with polysorbate 80; no pregnant or nursing women. PS 0-2; Prior cummulative doxorubicin dose of <=360 mg/m2; prior cummulative epirubicin dose of <=720mg/m2; No evidence or history of cardiomyopathy.